US dermatology top boss moves to Danish biotech firm

Draupnir Bio, which landed DKK 225m from four venture funds last year, will soon get a new boss in the form of Andrew Hotchkiss, who has previously worked as the CEO of Dermira. Further, the company is upgrading its board with a former Abbvie and Amgen executive.

Draupnir Bio CSO Simon Glerup | Photo: Draupnir Bio / PR

Danish biotech company, which raised DKK 225m (USD 36.2m) in capital in 2019  from a series of European venture funds including Novo Seeds will be changing its CEO.

Co-founder, CEO and Chief Scientific Officer Simon Glerup leaves the company, which is developing a tablet against blood clots in the heart. Now, he will function as the CSO and board member of the firm, while Andrew Hotchkiss, who has previously worked for Eli Lilly-owned biotech firm Dermira, will take on the role of CEO, according to a Wednesday press release.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

Further reading

Related articles

Trial banner

Latest news

See all jobs